Latest News and Press Releases

EXTON, PA, April 10, 2025 (GLOBE NEWSWIRE) -- As treatment approaches for cutaneous lupus erythematosus (CLE) continue to evolve, new data from Spherix Global Insights shed light on how specialists...

Autolus announces recent updates and financial results for the full year ended December 31, 2024.

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000th AVISE CTD test, marking a significant...

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the validation and regulatory submission for approval of new Systemic Lupus...

Data at ACR for ESK-001, oral TYK2 inhibitor, demonstrates potential as a high efficacy oral for treatment of Systemic Lupus Erythematosus (SLE).

EXTON, PA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a...

EXTON, PA, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The systemic lupus erythematosus (SLE) advanced treatment landscape is poised for evolution, with multiple new therapies in development to treat this...

– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...

Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024 ...